Radical Prostatectomy for Clinically Localized, High Risk Prostate Cancer: Critical Analysis of Risk Assessment Methods

Journal of Urology

Volumn 178, Issue 2, 2007, Pages 493-499

  Yossepowitch, Ofer ^a   Eggener, Scott E ^a   Bianco Jr , Fernando J ^a   Carver, Brett S ^a   Serio, Angel ^a   Scardino, Peter T ^a   Eastham, James A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

prostate; prostate specific antigen; prostatectomy; prostatic neoplasms; risk assessment

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED STUDY; HIGH RISK PATIENT; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; OUTCOME ASSESSMENT; PATHOLOGY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; RISK ASSESSMENT; SEMINAL VESICLE;

AGED; BIOPSY; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NOMOGRAMS; PROPORTIONAL HAZARDS MODELS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SEMINAL VESICLES;

EID: 34447109279     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.03.105     Document Type: Article

References (22)

1. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Blank K., Broderick G.A., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969
2. Grossfeld G.D., Chang J.J., Broering J.M., Li Y.P., Lubeck D.P., Flanders S.C., et al. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J Urol 165 (2001) 851
3. Ward J.F., Slezak J.M., Blute M.L., Bergstralh E.J., and Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 95 (2005) 751
4. Donohue J.F., Bianco Jr. F.J., Kuroiwa K., Vickers A.J., Wheeler T.M., Scardino P.T., et al. Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol 176 (2006) 991
5. Eastham J.A., Riedel E., Scardino P.T., Shike M., Fleisher M., Schatzkin A., et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 289 (2003) 2695
6. Scardino P. Update: NCCN prostate cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 3 suppl. (2005) S29
7. Mitchell J.A., Cooperberg M.R., Elkin E.P., Lubeck D.P., Mehta S.S., Kane C.J., et al. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol 173 (2005) 1126
8. Cooperberg M.R., Grossfeld G.D., Lubeck D.P., and Carroll P.R. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 95 (2003) 981
9. Graefen M., Karakiewicz P.I., Cagiannos I., Quinn D.I., Henshall S.M., Grygiel J.J., et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol 20 (2002) 3206
10. Gleave M., and Kelly W.K. High-risk localized prostate cancer: a case for early chemotherapy. J Clin Oncol 23 (2005) 8186
11. Eastham J.A. Multimodal treatment strategies combining neoadjuvant hormonal therapy and/or chemotherapy with radical prostatectomy in high-risk localised prostate cancer. Expert Opin Investig Drugs 13 (2004) 39
12. D'Amico A.V., Chen M.H., Roehl K.A., and Catalona W.J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125
13. Soloway M.S., Pareek K., Sharifi R., Wajsman Z., McLeod D., Wood Jr. D.P., et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 167 (2002) 112
14. Hurtado-Coll A., Goldenberg S.L., Klotz L., and Gleave M.E. Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: the Canadian experience. Urology 60 (2002) 45
15. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591
16. Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., Dorey F.J., Walsh P.C., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433
17. D'Amico A.V., Chen M.H., Roehl K.A., and Catalona W.J. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol 23 (2005) 4975
18. D'Amico A.V., Moul J.W., Carroll P.R., Sun L., Lubeck D., and Chen M.H. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95 (2003) 1376
19. Kattan M.W., Eastham J.A., Stapleton A.M., Wheeler T.M., and Scardino P.T. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 (1998) 766
20. Cooperberg M.R., Moul J.W., and Carroll P.R. The changing face of prostate cancer. J Clin Oncol 23 (2005) 8146
21. Clark P.E., Peereboom D.M., Dreicer R., Levin H.S., Clark S.B., and Klein E.A. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 57 (2001) 281
22. Dreicer R., Magi-Galluzzi C., Zhou M., Rothaermel J., Reuther A., Ulchaker J., et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 63 (2004) 1138